News
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy ...
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...
The FDA is allowing Sarepta to resume shipments of Elevidys (delandistrogene moxeparvovec) to ambulatory patients with Duchenne muscular dystrophy.
Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
The president overruled his HHS secretary and FDA chief, four people with knowledge of the decision tell POLITICO.
6don MSN
Who is Vinay Prasad? US FDA's top regulator exits agency after controversy over Sarepta gene therapy
Dr Vinay Prasad has resigned from the FDA after less than three months amid controversy over Sarepta Therapeutics' gene therapy and pressure from the White House. He plans to return to California to ...
3hOpinion
The New Republic on MSNPete Hegseth Unveils Return of Pro-Slavery Monument
U.S. Defense Secretary Pete Hegseth announced Tuesday that a Confederate memorial would be reinstalled in Arlington Cemetery ...
6d
TipRanks on MSNSarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy Use
Shares of Sarepta Therapeutics ($SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments ...
The Food and Drug Administration’s polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results